Yunnan First People's Hospital
Welcome,         Profile    Billing    Logout  
 41 Trials 
692 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xu, Wei
NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Recruiting
3
606
RoW
Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops
Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.
Myopia, Myopia Progression
12/26
12/27
NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Recruiting
3
104
RoW
C-BEAM Regimen, BEAM Regimen
The First Affiliated Hospital with Nanjing Medical University
Newly Diagnosed Peripheral T-cell Lymphoma
02/26
02/28
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2/3
226
RoW
ICP-248, Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Hematologic Malignancies
11/30
07/31
NCT04423926: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Recruiting
2
91
RoW
Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
The First Affiliated Hospital with Nanjing Medical University
PTCL, NOS, AITL, ALK- ALCL, Phase III-IV ALK+ ALCL, EATL
12/22
12/24
NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed
2
3
RoW
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma
11/21
12/21
NCT05241132: Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Recruiting
2
27
RoW
Tislelizumab plus chemotherapy, Cisplatin, Paclitaxel
Wei Xu
Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer, Immune Evasion, Tumor, Chemotherapy Effect
06/23
10/24
NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Recruiting
2
55
RoW
Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
The First Affiliated Hospital with Nanjing Medical University
EBV-Positive DLBCL, Nos
12/23
12/23
NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet recruiting
2
54
RoW
penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
01/24
02/26
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
NCT06594432: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

Not yet recruiting
2
40
RoW
R-CHOP+Z+MTX, R-CHOP+MTX
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma (DLBCL)
12/26
06/27
NCT04432714: Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting
2
81
RoW
Lenalidomide, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone
The First Affiliated Hospital with Nanjing Medical University
DLBCL, Untreated, MYC Gene Rearrangement
12/24
12/26
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated
1/2
23
RoW
TQ-B3525 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
11/23
11/23
NCT05323201: Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Recruiting
1/2
15
RoW
fhB7H3.CAR-Ts, B7H3 targeting chimeric antigen receptor T cells, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan
The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, IIT MediTech Co. Ltd
Hepatocellular Carcinoma
02/24
02/27
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated
1
20
RoW
ATG-019, KPT-9274, ATG-019 + Niacin ER
Antengene Therapeutics Limited
Solid Tumor, Non-Hodgkin's Lymphoma
10/23
10/23
TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
RoW
TT-01488 Tablets
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
10/26
10/28
NCT05173467: Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor

Not yet recruiting
N/A
60
RoW
Robot-assisted Invasion-controlled Surgery, Traditional-open Surgery
Wei Xu
Minimally Invasive Surgery, Spinal Metastases
12/22
12/23
NCT04432402: Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Recruiting
N/A
124
RoW
Lenalidomide, Rituximab, Gemcitabine, oxaliplatin
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma
12/22
12/24
Cryo-InitialAF, NCT04942834: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

Recruiting
N/A
286
RoW
Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation
Ruijin Hospital
Atrial Fibrillation, Persistent, Arrhythmias, Cardiac
07/25
01/26
NCT05777369: R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Not yet recruiting
N/A
30
NA
Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B-cell Lymphoma
08/23
08/24
NCT06211881: Chi-GVM Regimen for the Treatment of R/R PTCL

Recruiting
N/A
50
RoW
Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome
The First Affiliated Hospital with Nanjing Medical University
Relapsed/Refractory Peripheral T-cell Lymphoma
09/25
09/25
CSPC-DED-DLBCL-K09, NCT05784987: R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Not yet recruiting
N/A
60
NA
Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B-cell Lymphoma
01/24
01/25
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
EVL, NCT06250803: Early Pancreatic Stent Placement for Preventing PEP

Not yet recruiting
N/A
768
RoW
early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP)
The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital
Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis
03/26
03/26
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
NCT05426824: The Whole-course Management of Pegaspargase in ENKTL

Not yet recruiting
N/A
72
RoW
Pegaspargase（P-GOD）, Pegaspargase（PEMD）
The First Affiliated Hospital with Nanjing Medical University
Extranodal NK/T Cell Lymphoma
07/24
07/25
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Active, not recruiting
N/A
1000
RoW
No Intervention
Takeda
Lymphoma
06/26
06/26
NCT05896813: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Recruiting
N/A
30
RoW
CMOP+Chidamide
The First Affiliated Hospital with Nanjing Medical University
Newly Diagnosed Peripheral T-cell Lymphoma
01/25
01/25
EMPOWER CAD, NCT05755711: Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Active, not recruiting
N/A
399
Europe, US
Shockwave Medical Coronary IVL System
Shockwave Medical, Inc.
Coronary Artery Disease
12/24
04/28
NCT05343377: A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Not yet recruiting
N/A
72
RoW
circulate free methylated EBV DNA
The First Affiliated Hospital with Nanjing Medical University, Zhenjiang First People's Hospital, Changzhou First People's Hospital, Changzhou Second People's Hospital, Wuxi People's Hospital, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nantong University, Huaian first people's hospital, Yancheng First People's Hospital
Extranodal Natural Killer/T-cell Lymphoma
06/25
06/28
NCT06120426: En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.

Recruiting
N/A
182
RoW
total en bloc spondylectomy
Shanghai Changzheng Hospital, Peking University Third Hospital, Peking University People's Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Zhejiang University, Tianjin Hospital, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University
Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor, Surgery
07/25
07/27
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting
N/A
268
US
Aortix System, Aortix Pump
Procyrion
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
07/25
12/25
NCT05967949: A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
N/A
200
RoW
chidamide
The First Affiliated Hospital with Nanjing Medical University
PTCL
04/26
04/28
NCT05645302: Intensive Monitoring Scheme of Lidocaine Cataplasms

Recruiting
N/A
200
RoW
Lidocaine Cataplasms
Qianfoshan Hospital
Adverse Reaction to Drug
10/22
12/22
Yang, Yang
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Recruiting
3
426
RoW
Camrelizumab, radiotherapy
Zhigang Li, Jiangsu HengRui Medicine Co., Ltd.
Resectable Esophageal Squamous Cell Carcinoma
12/28
12/30
NCT05250843: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Recruiting
2/3
90
RoW
TACE/HAIC, Lenvatinib, Sintilimab, liver resection
Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
12/23
12/24
NCT06272214: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Recruiting
2
146
RoW
Adjuvant radiotherapy, Observation
Zhejiang Cancer Hospital
Adjuvant Radiotherapy
03/27
03/29
NCT06413342: Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting
2
191
RoW
Sintilimab
Zhejiang Cancer Hospital
Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy, Elderly Patients
06/26
06/28
IIT-2024-238, NCT06509568: Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

Recruiting
2
92
RoW
Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
08/25
08/26
NCT05738057: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
22
RoW
Camrelizumab, Gemcitabine Injection, Cisplatin injection, Cisplatin-Eluting Beads, D-TACE
Hua Li
Unresectable Intrahepatic Cholangiocarcinoma
03/25
03/26
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting
1/2
80
US, RoW
HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule
Shanghai Huaota Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, NSCLC
08/25
08/25
NCT05940610: The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure

Withdrawn
1/2
20
RoW
MSC-EVs
Third Affiliated Hospital, Sun Yat-Sen University
Acute-On-Chronic Liver Failure, Acute Liver Failure
09/24
10/25
NCT05881668: MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation

Withdrawn
1
30
RoW
MSC-EV
Third Affiliated Hospital, Sun Yat-Sen University
Liver Failure, Acute on Chronic
09/24
04/25
Neo-DRATEC, NCT03381651: Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma

Completed
N/A
147
RoW
Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
Zhejiang Cancer Hospital
Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery
02/21
02/23
NCT05764382: Remote Tai Ji for Low Back Pain

Recruiting
N/A
300
US
T'ai Chi and Qigong Rehabilitation, Usual care
New York Presbyterian Hospital, Center for Taiji and Qigong Studies & Wa-Qi.com
Low Back Pain
06/23
06/23
NCT04707053: Data Collection and Analysis in Brainstem Surgeries

Recruiting
N/A
150
Europe
Cantonal Hospital of St. Gallen
Brainstem Lesion, Surgery, Intraoperative Neurophysiologic Monitoring
12/23
12/25
NJFU, NCT06075290: the Difference of Follow-up Methods of Neonatal Jaundice

Recruiting
N/A
1000
RoW
internet plus model, control
Guizhou Provincial People's Hospital
Neonatal Jaundice
10/24
05/25
UTTS, NCT06743477: A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme

Not yet recruiting
N/A
5
RoW
Supergraft
Hu Peng
Stem Cell Transplantation
12/26
12/26
NCT05707520: Long-term Benefit of MPA in Liver Transplantation

Recruiting
N/A
500
RoW
enteric-coated mycophenolate (MPAs), None MPA
Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Transplant Rejection, Immunosuppressant Adverse Reaction
06/23
09/23
Hua, Yang
NCT06283758: Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)

Recruiting
N/A
30
RoW
focused power ultrasound mediate inferior perirenal adipose tissue modification, Sham-control group
Suzhou Municipal Hospital, The Affiliated Jiangning Hospital of Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Affiliated Hospital of Nantong University
Hypertension, Blood Pressure, Cardiovascular Diseases
07/26
10/26
UTTS, NCT06743477: A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme

Not yet recruiting
N/A
5
RoW
Supergraft
Hu Peng
Stem Cell Transplantation
12/26
12/26
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruiting
2
21
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
03/23
05/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Hourglass Sep 2024 - Sep 2024 : Updated data for adv solid tumors
Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/25
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
470
Europe, Japan, US
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Active, not recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
06/25
06/25
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
06/25
06/25
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
DS1471-079, NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Recruiting
4
78
US
Fruquintinib, Fruzaqla™
Takeda
Colorectal Cancer
02/28
02/28
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
51
Europe, Japan, US
BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
SWOG-S1600, NCT03757949: Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Active, not recruiting
3
203
US
Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Bladder Carcinoma
01/24
01/27
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Active, not recruiting
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
EA2183, NCT04248452: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Recruiting
3
314
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
03/28
03/28
NCT03941860: Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Active, not recruiting
3
1
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ixazomib Citrate, MLN 9708, MLN-9708, MLN9708, Ninlaro, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Multiple Myeloma
08/23
04/25
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
NCT04939090: Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Recruiting
3
360
US
Olanzapine, Megestrol Acetate, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
05/26
12/26
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
NCT06172296: Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
3
478
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, HEMATOPOIETIC STEM CELL TRANSPLANT, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Irinotecan, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Leukapheresis, Leukocyte Adsorptive Apheresis, Leukocytopheresis, Therapeutic Leukopheresis, White Blood Cell Reduction Apheresis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Survey Administration, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan, Hycamptamine, Topotecan Lactone, Tumor Resection, Vincristine, LCR, Leurocristine, VCR, Vincrystine
National Cancer Institute (NCI)
Ganglioneuroblastoma, Nodular, Neuroblastoma
12/29
12/29
ASCENDE-SBRT, NCT06235697: Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Recruiting
3
710
Canada, US
Radiation, Radiation SBRT only, ADT, Androgen Deprivation Therapy
Canadian Cancer Trials Group, NRG Oncology
Prostate Cancer
10/32
04/33
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
 

Download Options